Interim report January – June 2014 Strong order intake

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 18, 2014 at 2:45 AM

Interim report January – June 2014

Strong order intake · Net sales increased by 21 % to 111.0 (92.1) MSEK · Net profit amounted to 3.9 (7.6) MSEK (including non-recurring costs associated with the acquisition of AP&C of 6 MSEK) · Earnings per share amounted to 0.21 (0.48) MSEK · Cash at the end of the period 377.1 (166.7) MSEK · Order intake amounted to 16 (13) systems, and (11) systems were delivered in the period. · The order book contained 16 (13) systems by the end of the period · The acquisition of the metal powder manufacturer AP&C was completed on February 11. For the second quarter: · Net sales amounted to 46.1 (54.0) MSEK · Net profit amounted to 0.4 (7.5) MSEK · Order intake amounted to 10 (7) systems · 4 (7) EBM systems were delivered in the second quarter In the first 6 months we report a 21% increase in sales. Trailing twelve month sales amounts to 218.3 MSEK and earnings amount to 11.7 MSEK. The result includes non-recurring costs in the first quarter 2014 associated with the acquisition of AP&C of 6 MSEK. The order intake during the period amounts to 16 systems and the order book as of today comprises 17 systems. Acquisition of AP&C In February we acquired the powder producer AP&C from Raymor Industries in Canada. AP&C is a leading manufacturer of high quality metal powder and supplier of titanium powder to Arcam since 2006. Titanium powder is an important part of our offering and with this acquisition we have secured access to the best technology for the production of high quality metal powder for our customers. The acquisition is fully in line with our growth strategy and complements our EBM technology and product portfolio. The acquisition was completed on February 11, and is consolidated from this date. Business status We received 10 new orders during the quarter and we see a continued strong demand, particularly from the aerospace industry. The sales of our new large system, Arcam Q20, gains momentum and we have received 8 system orders. In June we launched Inconel 718® as a qualified material for use in Arcam’s EBM systems. With the introduction of the Inconel 718 our customers in the aerospace industry can now further expand the range of components that they produce in their EBM machines. The work to industrialize our technology with the major players within the aerospace and implant industries continue and we can now see good opportunities for volume orders during the year. At the same time, we see that the growing interest and knowledge in Additive Manufacturing and 3D printing creates interest within new segments. This may long term give opportunities for broadening of our product applications. Of the11 systems that were delivered during the first quarter the majority went to customers within the orthopedic implant or the aerospace industry. The cooperation with DiSanto is progressing and DiSanto ordered two new Arcam Q10 systems to meet the demand for finished EBM products. In the beginning of July we acquired our agent in the UK. We already have a support operation in the UK and with this new step we take responsibility for direct sales and support on the important UK market. Growth – organic and through acquisition In addition to the acquisition of AP&C we are in rapid organic growth. We thus continue to recruit qualified employees in order to meet the expectations from our customers. During the period we have strengthened our service office in China, the support organization in Sweden and the sales organization. Through the acquisition of AP&C and through recruitment the number of employees has increased from 55 to 113 since June 2013. We will maintain an ambitious recruitment pace in order to further develop our technology and offering and thus exploiting the present business situation. An order book of 17 systems, increasing aftermarket sales and a positive business situation lays a solid foundation for a continued growth in 2014. Mölndal, July 18, 2014 Magnus René, CEO The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on July 18, 2014 July 18, 2014 at 08.30 (CET). For further information please contact: Magnus René, CEO Arcam AB Tel: 0046 31 710 32 00, alt. cell: 0046 702 79 89 99, or e-mail: magnus.rene@arcam.com Arcam provides a cost-efficient Additive Manufacturing solution for production of metal components. The technology offers freedom in design combined with excellent material properties and high productivity. Arcam’s market is global with customers mainly in the orthopedic and aerospace industries. The company was founded in 1997 and is listed on NASDAQ OMX Stockholm, Sweden. Head office and production facilities are located in Mölndal, Sweden. Support offices are located in the US, UK, Italy and China. ________________________________________________________________________________ _ _______ Arcam AB • Krokslätts Fabriker 27A • SE-431 37 Mölndal, Sweden • 46-31-710 32 00 • www.arcam.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Princess Cruises Launches New Era at Celebration Key

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...